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Abstract: Factors involved in the spontaneous cleareance of a hepatitis C (HCV) infection are
related to both HCV and the interaction with the host immune system, but little is known about the
consequences after a spontaneous resolution. The main HCV extrahepatic reservoir is the peripheral
blood mononuclear cells (PBMCs), and their transcriptional profile provides us information of innate
and adaptive immune responses against an HCV infection. MicroRNAs regulate the innate and
adaptive immune responses, and they are actively involved in the HCV cycle. High Throughput
sequencing was used to analyze the miRNA profiles from PBMCs of HCV chronic naïve patients
(CHC), individuals that spontaneously clarified HCV (SC), and healthy controls (HC). We did not
find any differentially expressed miRNAs between SC and CHC. However, both groups showed
similar expression differences (21 miRNAs) with respect to HC. This miRNA signature correctly
classifies HCV-exposed (CHC and SC) vs. HC, with the has-miR-21-3p showing the best performance.
The potentially targeted molecular pathways by these 21 miRNAs mainly belong to fatty acids
pathways, although hippo signaling, extracellular matrix (ECM) interaction, proteoglycans-related,
and steroid biosynthesis pathways were also altered. These miRNAs target host genes involved
in an HCV infection. Thus, an HCV infection promotes molecular alterations in PBMCs that can
be detected after an HCV spontaneous resolution, and the 21-miRNA signature is able to identify
HCV-exposed patients (either CHC or SC).
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J. Clin. Med. 2019, 8, 849; doi:10.3390/jcm8060849 www.mdpi.com/journal/jcm
J. Clin. Med. 2019, 8, 849 2 of 22
1. Introduction
Nearly 71 million people live with chronic hepatitis C (CHC) infections, and 1.75 million new
hepatitis C virus (HCV) infections emerged worldwide [1]. Around 35% of patients with an acute HCV
infection will spontaneously clear the virus within six months of infection without any treatment [1,2].
Clinical features for this viral clarification are related to HCV interactions with the host innate/adaptive
immune system and host genetic factors. Thus, a low clearance rate is associated with the male gender,
HIV coinfection, hepatitis B virus (HBV) coinfection, specific genetic background as Afro-American
ethnicity, non-genotype 1 infection, older age, and high alcohol or drug consumption [3].
Nonetheless, little is known about the cost for the immune system after a clarification of an HCV
infection. Regarding cellular response, CD4+ and CD8+ T lymphocyte reactivity to HCV infections
persist for decades, although humoral responses seem to gradually decrease and disappear after
recovery from an HCV infection [4]. However, few studies have addressed these issues and their
clinical consequences with discrepant results. Patients cured of hepatitis C through treatment showed
a higher mortality rate overall than the general population [5,6], while mortality in a Danish cohort
with cleared HCV infections was similar to the general population [6]. Also, patients with a chronic
HCV infection are at higher risk of mortality and liver-related death than those patients who cleared
the infection [7].
Genetic background plays a key role in the antiviral immune response against HCV infection,
and epigenetic factors such as microRNAs (miRNAs) expression are essential [8]. These small RNAs
regulate the innate and adaptive immune response, and host miRNAs can directly target viral genomes
or cellular factors to positively or negatively regulate viral infection [9]. HCV relies heavily on cellular
factors for its life cycle, such as some host miRNAs which directly target its genome to enhance
viral replication and translation [10]. Also, an HCV infection directly impacts on cellular miRNAs
expression, disrupting innate immunity pathways to create a permissive environment for its viral
replication. Thus, some cellular miRNAs that repress essential HCV cofactors are downregulated by
HCV infection [8].
Although HCV mainly replicates within the liver, an extrahepatic replication of HCV has
been described in vitro and in vivo in a variety of cells, including peripheral blood mononuclear cells
(PBMCs), where HCV-RNA has been detected [11–13]. As PBMCs are one of the main HCV extrahepatic
reservoirs, the HCV lymphotropism leads to abnormal B-cell activation and the development of
lymphoproliferative and autoimmune disorders [14], such as non-Hodgkin’s lymphoma and mixed
cryoglobulinemia, which is the most common extrahepatic manifestation of a chronic HCV infection [15].
The HCV lymphotropic variants likely constitute a distinct but parallel source for viral persistence and
immune escape within chronically infected patients [12]. Also, the dysfunction of HCV-infected PBMCs
leads to immune function decline, and it becomes more difficult for the host to clear intrahepatic
HCV [16]. Moreover, recent studies have shown that PBMCs may reflect the alterations of intracellular
pathways occurring during HCV-related liver diseases [17], being the innate antiviral response against
acute HCV not restricted to the liver [18].
Therefore, we propose that the miRNA profile of PBMC from HCV-exposed patients could give
us insight into deregulated miRNAs after HCV resolution and their possible immune consequences.
Thus, we aim to analyze the expression profile of miRNAs from HCV chronic naïve patients and
individuals who spontaneously resolved an HCV infection with respect to healthy donors. The analysis
of differentially expressed miRNAs in participants with different HCV history allowed us to identify a
common HCV signature in chronic and spontaneous clearance patients and, therefore, their putative
deregulated pathways.
2. Experimental Section
An extensive description of the material and methods can be found in the Supplementary Materials.
Samples were recruited from Hospital Universitario Virgen de Valme (Seville), Hospital
Universitario Marqués de Valdecilla (Santander), and Hospital Universitario Infanta Leonor (Madrid)
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from 2014 to 2017. All samples were processed at the National Center for Microbiology (Majadahonda).
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected
in a priori approval by the Ethics Committee of Institute of Health Carlos III, number CEI PI 11_2015-V4,
approved on 2 September 2015. Written informed consent was obtained from all patients involved.
2.1. Patient Groups
Caucasian patients (n = 96) were recruited and grouped by (a) HCV spontaneous clarifiers (SC),
individuals who spontaneously resolved an HCV infection (positive serum antibody and negative
PCR), with a minimum of six months of follow-up from the diagnosis, and remaining as such thereafter;
(b) chronic hepatitis C (CHC) treatment-naïve patients (detectable HCV RNA by PCR for at least six
months); and (c) healthy controls (HC) that were never infected with HCV (antibody and PCR negative).
All groups were gender balanced to avoid sex bias, and controls were age-matched with SC and CHC
groups. Only participants with no advanced liver fibrosis were selected to have a homogeneous cohort
and to limit confounding factors.
The general exclusion criteria for all group of patients are as follows: individuals below 18 years
old; previously HCV treatment; clinical evidence of hepatic decompensation; alcohol-induced liver
injury; HBV-associated antigen/antibody or anti-HIV antibody; active drug or alcohol addiction;
opportunistic infections; and other concomitant diseases such as diabetes, nephropathies, autoimmune
disease, hemochromatosis, cryoglobulinemia, primary biliary cirrhosis, Wilson´s disease, α-antitrypsin
deficiency, neoplasia, and pregnancy.
2.2. Clinical Records
HCV-related clinical and epidemiological data were obtained from medical records as the year of
infection, time since spontaneous clarification, route of transmission, fibrosis stage, HCV viral load,
HCV genotype, and genotype of rs12979860 polymorphism at interferon lambda 4 (gene/pseudogene)
(IFNL4). The liver stiffness measurement (LSM) was assessed by transient elastometry (FibroScan®,
Echosens, Paris, France) and expressed in kilopascals (kPa). Subjects were stratified according to
cut-offs of LSM: <7.1 kPa (F0–F1: absence or mild fibrosis) and 7.1–9.4 kPa (F2: significant fibrosis).
The clinical characteristics of metabolic status and biochemical parameter of liver function were also
recorded (see Clinical Records at Supplementary Material).
2.3. Collection of Biological Samples
PBMCs were isolated within the first 4 h after blood extraction. The total RNA, including miRNAs,
was isolated with the miRNeasy Mini kit (Qiagen). Quality and integrity were evaluated by the
Bioanalyzer 2100 with Agilent RNA 6000 Nano kit (Agilent).
2.4. Analysis of miRNA Expression by High Throughput Sequencing
Small RNA library synthesis and sequencing were performed at the Centre for Genomic Regulation
(CRG) at Barcelona (Spain). Briefly, small RNA libraries were constructed with Illumina’s TruSeq
Small RNA kit v.4 (Illumina) from 1 microgram of total RNA, following manufacturer´s instructions.
Sequencing was performed on the Illumina HiSeq2500, Single-Read, 50 nts (1 × 50). Four pools of
24 barcoded samples were prepared, and each pool was sequenced on one line of the same run to limit
batch effect.
Raw data were analyzed with a specific bioinformatic pipeline for the identification of known
and novel miRNAs, which is extensively described in the Supplementary Material. Quality control
was performed with FastQC (v.0.11.3); adapter sequences were trimmed with cutadapt (v.1.13) and
processed with miRDeep2 (v.0.0.7), which identify known and novel miRNAs. miRBase v.20 and
GRCh38 reference genome assembly were used as reference databases.
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2.5. miRNA Validation by qRT-PCR
Sixty-six additional individuals were selected for validation purpose, where 22 individuals
corresponded to each group of study (HC, SC, and CHC). Five hundred ng of total RNA was reverse
transcribed into complementary DNA with the qScript microRNA cDNA synthesis kit, following the
manufacturer instructions. Individual miRNAs were quantified in a SYBR green quantitative PCR.
Sequences of the miRNA nucleotides were extracted from the miRBase Release 21 (www.mirbase.org)
(Table S6). The PCR efficiency of each miRNA amplicon was evaluated, and efficiencies higher than
1.9 were accepted. Real time reactions were performed on a Roche LightCycler 480. Endogenous
control selection was performed according to the stability of their gene expression in the three groups
of study. Raw data were exported to Factor qPCR to normalize and remove multiplicative between-run
variations of PCR experiments with multiple plates. [19]. Data were analyzed using the ∆∆CT method.
For extended information, see the Experimental Section in the Supplementary Materials.
2.6. miRNA-Based Target Prediction and Pathway Enrichment Analysis
The web-based computational tool DIANA-miRPath v3.0 was used for the in silico target
identification of the significantly differentially expressed (SDE) miRNAs, which is based on
experimentally supported target predictions. This tool also performs a pathway union analysis
of miRNAs targets by the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Enrichment
p-values (Fischer’s exact test with hypergeometric distribution) were corrected for the false discovery
rate (FDR) (p ≤ 0.05). Next, the SDE miRNAs were subjected to a target-based pathway enrichment
analysis to identify miRNA-mRNA regulatory networks with miRNet.
2.7. Statistical Analyses
Thirty-two samples for each group (HC, SC, and CHC) were sequenced. The sample size for
each group was calculated according to the RnaSeqSampleSize calculator [20], which established a
minimum of 27 samples per group. Calculates were performed by using the following parameters:
100 minimum average read counts; an estimated dispersion of 0.4, which is used for human data; and a
minimum fold change of 2. Also, a specific analysis on miRNA sequencing shows that 32 individuals
per group are more than enough to detect a minimum 2 fold change with a false discovery rate of
5% [21].
We used Principal Component Analysis (PCA) to visualize whether the experimental samples
were clustered according to the groups of patients and to identify the unwanted source of noise.
Currently, there are no specific software packages designed to normalize miRNA sequencing
data; for this reason, three normalization methods commonly used for RNA sequencing analysis have
been used: (1) reads per kilobase million (RPKM), by the Differential gene expression analysis based
on the negative binomial distribution (DESeq) R package (v.1.28.0); (2) trimmed mean of M-values
normalization method (TMM), by the Empirical Analysis of Digital Gene Expression Data in R (EdgeR)
(v.3.18.1); and (3) upper quantile normalization (UPERQ), by NOISeq R package (v.2.14.1).
SDE miRNAs were calculated by a fold change (FC) > 2 and a statistically significant t-test
p value < 0.05 adjusted by FDR using the Benjamin–Hochberg correction. (1) DESeq fit a generalized
linear model for each miRNA with the fold change estimate shrunken by empirical Bayes; the function
nbionmTest was used to estimate differences between groups. (2) edgeR used a likelihood ratio test
for determining the differential expression among groups of patients, and it was performed with the
glmFit() and glmLRT() functions. (3) NOISeqBIO is a nonparametric method that improves the control
of the high FDR in experiments with biological replicates.
A Venn Diagram was performed to determine the overlapping of SDE miRNAs, which were
defined as common SDE miRNAs in the three methods of normalization and statistical analysis.
The overlapping list of each group of comparison was selected for a subsequent analysis.
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We also conducted a partial least square discriminant analysis (PLS-DA), which is used
for predictive and descriptive modeling as well as for discriminative variable selection [22] in
high-dimensional data. PLS-DA is a supervised learning method which uses the normalized miRNA
expression profile for analysis. We used the HCV-exposed (SC and CHC) or non HCV-exposed group
as the response variable and the expression profile of the SDE miRNAs between those groups as
explanatory variables. Also, the Variable Importance for the Projection (VIP) criterion was used to
identify the contribution of each specific predictor for both the explained variability on the response
and the explained variability on the predictors. PLS-DA and VIP were performed with the caret
package (v.6.0-81) included in the R Project for Statistical Computing.
For the descriptive study of clinical and demographic data of the patients, continuous variables
were summarized as the median and the interquartile range and categorical variables were summarized
as absolute numbers (%). Significant differences between categorical data were calculated using the
chi-squared test or Fisher´s exact test. The Kruskal–Wallis and Mann–Whitney U tests were used to
compare continuous variables among independent groups. IBM® SPSS Statistics (v.22) and statistical
software R (v.3.2.0) (www.r-project.org) were used for all statistical analyses.
3. Results
3.1. Clinical Characteristics of Each Group of Patients
Table 1 shows the HCV-related epidemiological and clinical characteristics of the three groups
of participants included in our study: CHC, SC, and HC. The time since clearance of SC individuals
ranged from 0.6 to 47 years. Regarding CHC patients, the time of infection ranged from 1 to 38 years.
Only some variables showed significant differences between groups (p < 0.05), such as the transmission
route of HCV infection, where CHC showed a higher proportion of IDUs. Moreover, the SC group
showed a significantly higher proportion of the favorable IFNL4 rs12979860 CC genotype than CHC
and HC, as expected.
Table 1. HCV-related clinical and epidemiological characteristics of 96 patients with miRNA
sequencing data.
Patients Characteristic All Patients CHR SC HD p Value
No. 96 32 32 32
Gender (male %) 48 (50%) 16 (50%) 16 (50%) 16 (50%) 1.000
Age at recruitment (years) 50.5 (45.0; 59.0) 50.5 (43.0; 62.2) 54.5 (47.0; 60.5) 48.5 (42.5; 56.2) 0.171
Time of HCV infection (years) (n = 32) - 24.0 (17.5; 34.0) - -
Time of HCV spontaneous clearance
(years) (n = 23) - - 3 (2; 13) - -
Transmission route (No.) <0.001
IDUs 19 (19.8%) 13 (40.6%) 6 (18.8%) -
Transfusion 8 (8.3%) 6 (18.8%) 2 (6.3%) -
Medical Procedure 6 (6.3%) 5 (15.6%) 1(3.1%) -
Unknown 63 (65.6%) 8 (25.0%) 23 (71.9%) -
Fibrosis stage (No.) 41 32 9 0.378
F0 6 (14.6%) 5 (15.6%) 1 (11.1%) -
F1 32 (78%) 25 (78.1%) 7 (77.8%) -
F2 1 (2.4%) 0 (0%) 1 (11.1%) -
HCV viral load (UI/mL) × 106 - 1.5 (0.6; 3.3) -
HCV genotype (n = 32) -
1 - 22 (68.8%) -
2 - 3 (9.4%) -
3 - 1 (3.1%) -
4 - 6 (18.8%) -
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Table 1. Cont.
Patients Characteristic All Patients CHR SC HD p Value
IFNL4 (IL28B) SNP (n = 95) 0.004
CC (favourable) 42 (44.2%) 6 (18.8%) 20 (64.5%) 16 (50%)
CT 41 (43.2%) 20 (62.5%) 7 (22.6%) 14 (43.8%)
TT 12 (12.6%) 6 (18.8%) 4 (12.9%) 2 (6.3%)
Values expressed as absolute numbers (%) and median (percentile 25; percentile 75). p-values were estimated
by nonparametric Kruskal–Wallis test and Mann–Whitney for continuous variables and by the Chi-square test
for categorical variables. Statistically significant differences are shown in bold. Abbreviation: HCV, hepatitis
C virus; BMI, body mass index; IDUs, intravenous drug users; LS, liver stiffness; IFNL4, interferon lambda 4
(gene/pseudogene).
Table 2 shows the metabolic status of the patients. Most of the data were only available for CHC
and SC patients. The lipid profile analysis did not show significant differences between groups. High
AIP values were found in both groups. Biochemical parameters related to liver function such as liver
enzymes GOT, GPT, GPT > 40 mg/dL, GGT, and APRI index, showed higher values in the CHC group
(p = 0.002, p < 0.001, p = 0.005, p = 0.039, and p = 0.032, respectively).
Table 2. Clinical characteristics of metabolic and liver status.
Patients characteristic All Patients C SC HC p Value
Total number 96 32 32 32
Weight (kg) (n = 70) 71.8 (61.1; 80.0) 65.0 (58.0; 75.3) 73.3 (64.2; 87.5) 75.8 (64.0; 88.2) 0.274
BMI (n = 64) 24.9 (22.2; 27.5) 24.8 (21.6; 26.7) 24.9 (21.6; 28.4) 25.2 (22.8; 29.0) 0.655
Glucose (mg/dL) (n = 64) 89.0 (80.2; 102.5) 89. 0 (80.2; 108.5) 88 (80.5; 102.5) - 0.697
Glucose ≥110 mg/dl 13 (20.3%) 8 (25.0%) 5 (15.6%) - 0.351
Insulin (mlU/L) (n = 23) - 8.5 (5.5; 13.9) - -
HOMA-IR (n = 23) - 1.75 (1; 3.2) - -
Lipid profile
Total cholesterol mg/dL
(n = 63)
186.0
(161.0; 207.0)
177.5
(156.25; 206.2)
192.0
(173.0; 207.0) - 0.132
TC ≥200 mg/dL 19 (30.2%) 9 (28.1%) 10 (32.3%) - 0.721
LDL (n = 56) 105.0 (85.0; 125.0) 104.5 (85.0; 131.2) 107.0 (89.0; 116.0) - 0.918
LDL ≥130 mg/dL 10 (18.2%) 8 (25.0%) 2 (8.7%) - 0.122
HDL mg/dL (n = 55) 57.0 (46.0; 65.0) 57.5 (46.2; 65.0) 55.0 (46.0; 66.0) - 0.898
TG (n = 56) 91.5 (66.7; 149.0) 92.0 (61.0; 152.0) 91.0 (72.0; 137.0) - 0.676
TG ≥200 mg/dL 3 (5.4%) 2 (7.4%) 1 (4.3%) - 0.737
Homocysteine (µmol/L) (n = 22) 13.4(10.8; 16.3) 13.7 (12.1; 16.6) 12.0 (10.2; 16.1) - 0.553
High level (>15) 7 (11.1%) 3 (9.7%) 4 (12.5%) - 0.722
LDL/HDL (n = 55) 1.96 (1.5; 2.3) 1.8 (1.4; 2.5) 1.8 (1.5; 2.3) - 0.645
AI (TC/HDL) (n = 41) 3.1 (2.8; 3.8) 3.1 (2.7; 3.9) 3.3 (3.0; 3.8) - 0.588
Low risk 38 (39.6%) 24 (75.0%) 14 (43.8%) - 0.903
Moderate risk 3 (3.1%) 2 (6.3%) 1 (3.1%) - 0.903
AIP (Log(TG/HDL)]) (n = 41) 0.19 (0.07; 0.47) 0.20 (0.02; 0.49) 0.18 (0.08; 0.35) - 0.948
AIP High risk (>0.21) 19 (45.2%) 13(48.1%) 6 (40%) - 0.611
LCI (TC*TG*LDL)/HDL × 103 (n = 42) 31.4 (22.2; 50.9) 30.7 (14.5; 58.3) 34.8 (24.4; 36.8) - 0.948
Biochemical parameters of liver function
GOT (n = 63) 34.0 (24.0; 42.0) 37.0 (31.2; 45.0) 24.0 (18.0; 37.0) - 0.002
GOT ≥40 mg/dL 14 (22.2%) 9 (28.1%) 5 (16.1%) - 0.252
GPT (n = 64) 33.0 (21.5; 52.5) 41.0 (32.2; 59.7) 25.5 (17.2; 37.5) - <0.001
GPT ≥40 mg/dL 25 (39.1%) 18 (56.3%) 7 (21.9%) - 0.005
GGT (n = 62) 32.5 (21.7; 60.2) 40.0 (25.0; 69.0) 24.0 (15.0; 57.0) - 0.039
GGT ≥50 mg/dL 22 (22.9%) 12 (12.5%) 10 (31.25) - 0.596
ALP (n = 62) 74.0 (58.0; 85.7) 75.5 (57.7; 89.2) 73.5 (58.2; 83.5) - 0.472
TB (n = 63) 0.6 (0.5; 0.8) 0.6 (0.5; 0.9) 0.5 (0.4; 7.0) - 0.116
Albumin (n = 45) 4.4 (4.2; 4.6) 4.4 (4.2; 4.6) 4.3 (4.2; 4.5) - 0.465
APRI (n = 57) 0.4 (0.3; 0.6) 0.5 (0.3; 0.7) 0.3 (0.3; 0.4) - 0.032
FIB-4 (n = 55) 1.4 (1.0; 2.0) 1.4 (1.0; 1.8) 1.4 (1.1; 2.0) - 0.748
Values expressed as absolute numbers (%) and median (percentile 25; percentile 75). p-values were estimated
by nonparametric Kruskal–Wallis test and Mann–Whitney for continuous variables and by the Chi-square test
for categorical variables. Statistically significant differences are shown in bold. BMI, body mass index; TC, total
cholesterol; LDL, low density lipoprotein; TG, triglycerides; HDL, high density lipoprotein; AI, atherogenic index,
cut-off values were: low risk <5% for men and <4.5% for women, moderate risk 5–9 for men and 4.5–7 for women;
AIP, atherogenic index for plasma considering high risk AIP > 0.21; LCI, lipoprotein combine index defined as the
ratio of TC*TG*LDL to HDL-C; GOT, glutamate oxaloacetate transaminase; GPT, glutamic-pyruvic transaminase;
GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; TB, total bilirubin; APRI, AST to platelet ratio index;
FIB-4, fibrosis-4 index for liver fibrosis.
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3.2. Differentially Expressed miRNAs Between Groups
The raw sequencing data have been deposited in the ArrayExpress repository (EMBL-EBI) under
accession number E-MTAB-8023. We identified a total of 1881 known miRNAs (of 2822 recorded in
miRBase v.20) with more than 5 counts, plus 137 putative de novo miRNAs that fulfilled the selection
criteria (see details in the Supplementary Material). The 137 de novo miRNAs are listed in Table S1.
On average, 10.9 million reads per sample were obtained, which is an appropriate depth for an
expression analysis [23]. The 54% of the reads could be mapped to the reference genome, (quantifier
log), and 66.6% of the miRNAs in miRBase were detected. Also, we have performed our analysis on a
large data set (96 samples). The number of samples plays a more significant role in determining the
power than the read counts [24], as increasing the number of replicates significantly improves the
detection power over an increased sequencing depth.
The principal component analysis (PCA) of each normalized set of data (by DESeq, edgeR,
and NOISseq) was performed (Figure 1). In the three PCAs, the HC group formed independent clusters
with the three normalization methods and both CHC and SC grouped together.
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Figure 1. Unsupervised Principal Component Analysis (PCA) of the data normalized by the three
methods of normalization (a) DESeq, (b) edgeR, and (c) NOIseq. Each symbol represents the miRNA
profile from one of the 96 participants of the study. All methods show an overlap between HCV chronic
naïve (CHC) patients and spontaneously clarified HCV (SC) individuals.
Differential expressions analyses’ results showed similar fold changes for each normalization and
statistical method (Table S2).
3.2.1. miRNAs Associated with HCV Spontaneous Clarification
When we compared the SC vs. HC groups, 95 SDE miRNAs were common to the three analysis,
where 122 miRNAs were identified by DESeq, 128 miRNAs by edgeR, and 125 miRNAs by NOISeq
(Figure 2A). The identification of all SDE miRNAs and their fold changes are listed in Supplementary
Table S3. The hierarchical cluster analysis of the common 95 SDE miRNAs showed distinct patterns of
miRNA expression between groups of comparison. We identified 61 miRNAs downregulated and
34 upregulated in SC (Figure 3A). From the 95 SDE miRNAs, 11 of them were de novo miRNAs
(hsa-chr1_2076, hsa-chr1_1467, hsa-chr2_4858, hsa-chr5_13836, hsa-chr8_20936, hsa-chr10_23092,
hsa-chr12_29164, hsa-chr16_34569, hsa-chr18_37981, hsa-chr19_38809, and hsa-chrX_43884), located at
chromosomes 1, 2, 5, 8, 10, 12, 16, 18, 19, and X, respectively.
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3.2.2. miRNAs Associated with HCV Chronic Infection
When CHC and HC were compared, 71 SDE miRNAs were identified by DESeq, 83 by edgeR,
and 33 by NOISeq. The three methods shared 23 SDE miRNAs (Figure 2B). The hierarchical cluster
analysis of the common 23 SDE miRNAs showed two main clusters which corresponded to the patient
groups (HC and CHC) (Figure 3B). The majority of SDE miRNAs (n = 18) were downregulated in
CHC compared to HC, and only five miRNAs were upregulated during an active HCV infection
(Supplementary Table S4). One of the downregulated SDE miRNAs corresponded to one putative de
novo miRNA located at chromosome 16 (hsa-chr16_34569). Twenty-one out of 23 SDE miRNAs were
the same to those identified in the SC comparison with respect to HC.
3.2.3. Analysis of miRNAs Between CHC and SC Patients
Similar miRNA expression patterns were identified in SC subjects and CHC patients, as the
differential expression analysis did not find any common SDE miRNAs between the three statistical
methods (Figure 2C). EdgeR identified ten SDE miRNAs, DESeq three, and NOISeq one. Three SDE
miRNAs were common to DESeq and edgeR, and only one was common to NOISeq and edgeR
(Figure 2C, Supplementary Table S5). These data substantiated our PCA findings and were as
commented above: SC and CHC clustered together and separated from HC. Therefore, our data
suggest that HCV-exposed patients (SC and CHC) show a specific miRNA profile.
3.2.4. Common miRNAs in CHC and SC versus HC Subjects
Finally, we searched for miRNA patterns shared by HCV-exposed (SC and CHC) individuals.
To achieve this goal, we compared the common SDE miRNAs identified between SC and HC (95 SDE
miRNAs), with the common SDE miRNAs between CHC and HC (23 SDE miRNAs). As a result,
21 SDE miRNAs were identified as mutual to both analyses, indicating an HCV-specific signature
of miRNAs in PBMCs. From the 21 miRNAs, 16 were downregulated and five were upregulated in
HCV+ exposed (CHC and SC groups). Also, the heatmap and unsupervised hierarchical clustering of
these 21 common SDE miRNAs showed us that CHC patients and SC individuals clustered together
and separated from HC (Figure 3C). Therefore, almost all dysregulated miRNAs detected in CHC
(except hsa-miR-3648 and hsa-miR-1908-3p) were also disrupted in SC individuals, suggesting a similar
miRNA-mediated posttranscriptional regulation in individuals who have been exposed to an HCV+
infection, either to an acute or chronic active infection. Additionally, the fold changes detected for the
21 SDE miRNAs were highly similar in both comparisons, indicating an analogous dysregulation of
miRNA-related pathways (Figure 4). Only hsa-miR-7641 showed slight differences in the magnitude
of log2FC, not in the direction, but these differences were not statistically significant.
To explore the discrimination ability of these 21 miRNAs, we performed a PLS-DA analysis.
The classification between HCV-exposed (SC and CHC) and non-exposed (HC) groups were done
without no error, with an accuracy = 1, sensitivity = 1, and specificity = 1 (p < 0.001). The VIP values
for each miRNA is shown in Figure 5. The hsa-miR-21-3p showed the highest VIP score. Therefore,
this 21 SDE miRNAs profile is adequate for discrimination between previously HCV-exposed and
non-exposed individuals.
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Figure 5. Variable Importance in Projection (VIP) calculated for each 21 SDE miRNAs.
3.3. miRNA Validation
Two miRNAs were selected for validation in a new data set, the has-miR-21-3p, which is the
miRNA with the highest VIP score, and the has-miR-23a-5p. The endogenous control gene with
the best stability value was the RNU44. Patients characteristics can be accessed in Supplementary
Table S7. Both miRNAs were validated, showing a reduced expression in HC vs. HCV-exposed (SC and
CHC) individuals and no statistically significant differences between CHC and SC (see Supplementary
Materials, Figure S1 and Table S8).
3.4. Functional Enrichment Analysis of Targets from miRNAs Associated with HCV Spontaneous Clarification
and Chronic HCV Infection
Targets from miRNAs associated with HCV+ exposed individuals were explored for enrichment
in known KEGG pathways. Among the 21 SDE miRNAs identified between CHC patients and SC
individuals with respect to HC, eight significantly enriched pathways (p < 0.05) were identified
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based on experimentally validated data (Figure 6, Table 2). The most significant pathways
were those related to fatty acid metabolism (hsa00061, hsa01212, and hsa00062), where miRNAs
hsa-miR-21-3p, hsa-miR-125a-5p, hsa-miR-125b-5p, and hsa-miR-124-3p have key roles. All these
miRNAs, except miR-21-3p and miR-124-3p, were downregulated in CHC and SC regarding HC.
Other significant pathways targeted by these miRNAs were (a) the Hippo signaling pathway
(hsa04390), identified by 27 targeted genes of 4 SDE miRNAs (hsa-miR-125a-5p, hsa-miR-125b-5p,
hsa-miR-582-3p, and hsa-miR-3960); (b) the extracellular matrix (ECM) interaction pathway (hsa04512),
which is represented by 24 genes targeted by 3 SDE miRNAs (hsa-miR-23a-5p, hsa-miR-122-5p,
and hsa-miR-124-3p); (c) two proteoglycans-related pathways (hsa05205, hsa00514), represented in
total by 105 genes targeted by 6 SDE miRNAs (hsa-miR-21-3p, hsa-miR-122-5p, hsa-miR-124-3p,
hsa-miR-125a-5p, hsa-miR-125b-5p, and hsa-miR-582-3p); and (d) the steroid biosynthesis (hsa00100),
denoted by 5 targeted genes of 3 SDE miRNAs (hsa-miR-21-3p, hsa-miR-23a-5p, and hsa-miR-124-3p).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 12 of 22 
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3.5. Network of miRNAs and their targeted genes
The 21 SDE miRNAs were analyzed with miRNEt (Figure 7). This analysis identified nine
miRNAs (miR-124-3p and miR-1296-3p upregulated and miR-125a/b-3p, miR-122-5p, miR1229-3p,
miR-1248, miR-3196, and miR-7641 downregulated in either CHC or SC individuals) with 39 target
gene interactions corresponding to the HCV KEGG pathway. Thus, the miR-124-3p is critical in this
pathway, as they directly target 18 HCV infection-related genes. Therefore, our results suggest a
dysregulation of genes associated with HCV infection, either in an active or previous acute HCV status.
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4. Discussion
Our major purpose was to find a similar deregulation of miRNAs in both CHC patients and SC
patients with respect to the HC group. Therefore, a spontaneous clarification of HCV during an acute
infection leads to molecular changes that can be observed later in the miRNA profile of PBMCs.
HCV infection in hepatic cells triggers an extensive dysregulation of host miRNAs to positively
or negatively regulate its life cycle through directly targeting its genome and genes associated with
cellular signaling pathways [25,26]. Our study is the first report showing a disruption of miRNA
expressions in PBMCs of HCV-previously exposed patients, where this disruption persists after an
HCV spontaneous resolution.
Patients for the present study were recruited just before the inclusion of the new direct active
antivirals (DAAs) in the Spanish public healthcare system. At that time, only patients with advance
fibrosis were treated with the classic interferon and ribavirin treatment, while the rest of individuals
wait to be treated with DAAs. For this reason, we could recruit CHC naïve patients with a long time of
infection (up to 38 years). Although all CHC patients showed no advanced fibrosis, the values of GOT,
GPT, GGT, and APRI were significantly higher than in SC individuals. This different liver enzyme
profile strengthens our claim on miRNA profile similarity in SC and CHC patients.
Our findings were reached through three different methods of statistical analysis since there is
no clear consensus on the appropriate normalization method to be used in miRNA sequencing data.
The choice of the normalization method is the primary factor that affects the results of a high-throughput
differential expression analysis, and this will inevitably impact the downstream analysis [27]. For this
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reason, we have only selected those SDE miRNAs identified by the three methods to limit false positives
results and to secure the validity of our findings. This method of analysis, together with the use of a
large cohort of patients for a high-throughput analysis, strengthen the confidence of our results.
We identified a signature of 21 SDE miRNAs disrupted in CHC and SC individuals, with respect
to HC. These miRNAs were dysregulated with similar fold changes and the same direction in both
comparisons, which indicates that either a previous acute or active chronic HCV infection similarly
disrupts miRNA profiles of PBMCs over time. These 21 SDE miRNAs can differentiate HCV-exposed
(SC and CHC) from HC without classification error, being that hsa-miR-21-3p is the variable with the
best performance. This miRNA is upregulated in our HCV-exposed group of patients, which is in
accordance with previous in vitro studies [28]. HCV induces hsa-miR-21-3p, which negatively regulates
IFN-alpha signaling, contributing thus to an evasion of the host immune system. For this reason,
Chen et al. stated that has-miR-21-3p might be a potential therapeutic target for antiviral intervention.
Five out of 21 SDE miRNAs have not been previously detected in PBMCs (hsa-miR-7641,
hsa-miR-1248, hsa-miR-1229-3p, hsa-miR-1296-3p, and hsa-miR-4284). Only the hsa-miR-7641 has
shown a previous relation to HCV infections [29], where its expression was downregulated in severe
versus mild CHC. Our data also showed a downregulation in HCV-exposed patients versus HC. On
the other hand, two miRNAs (hsa-miR-1296-3p and hsa-miR-4284) have shown relations to chronic
hepatitis B (CHB). The hsa-miR-1296-3p is expressed in hepatocellular carcinoma of chronic hepatitis B
infected patients [30], while plasma levels of the hsa-miR-4284 seem to predict early virological response
to interferon alpha therapy in CHB patients [30,31], and it is upregulated in recurrent hepatocellular
carcinoma [32].
To the best of our knowledge, this is the first study reporting the miRNA profile of SC patients. Some
others have slightly addressed differences between CHC and HC individuals, but no high-throughput
assays have been performed. The widely studied hsa-miR-122 was significantly downregulated in
HCV-exposed patients (CHC and SC) in our data set. Despite differences in the study design,
similar results have been previously observed in either liver or PBMCs of CHC patients [33].
The expression profiling of PBMC associated miRNAs was also compared between responders
and non-responders to PEG-IFN/RBV antiviral therapy. His and colleges identified that circulating
PBMC associated miR-125b was a predictive marker for SVR with significantly reduced levels of
miR-125b in responders versus non-responders [34], but no control group was used. Our results indicate
that this miRNA is downregulated in HCV-exposed. Matsuura et al. [29] analyzed miRNA expression
in CHC patients compared to HC, but they performed this analysis in plasma and extracellular
vesicles not in PBMCs. Also, unlike our patients, in Matsuura et al., CHC patients showed mild and
advanced fibrosis. We have compared our results with this study, and only two miRNAs are common,
hsa-miR-3960 and hsa-miR-4787-5p.
We explored all published data sets of HCV infections to validate our data. Unfortunately, as no
similar studies are freely available, we could not validate the classification performance of this 21
miRNA in other data sets.
4.1. Lipid Metabolism Disruption in HCV-Exposed Patients
The enriched pathways analysis of the targets regulated by the HCV signature of 21 SDE miRNAs
showed that the fatty acid metabolisms pathways were the most significant, where hsa-miR-21-3p
and miR- 124-3p were upregulated while hsa-miR-125a-5p and hsa-miR-125b-5p were downregulated.
These miRNAs have been identified as disrupted in HCV-infected hepatocytes, but this is the first
report showing a lipid metabolism-related miRNAs disruption in PBMCs of HCV-exposed individuals.
Metabolic pathways related to cholesterol and lipoproteins biosynthesis have been shown to play
a critical role in an HCV life cycle and are essential for HCV uptake, formation, and replication of new
viral elements [25,35]. In this sense, HCV hijacks and manipulates fatty acid flux to create specific
lipid-enriched microenvironments to promote its life cycle [36,37]. This deregulation directly affects
the innate antiviral response, liver disease progression, and the response to antiviral therapies [38].
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Emerging evidence demonstrates that miRNAs are critical regulators of lipid biosynthesis, fatty acid
oxidation, and lipoprotein formation and secretion [39]. Also, not only is the deregulation of lipid
metabolism during an HCV infection limited to hepatocytes but PBMCs may reflect the alterations of
intracellular pathways occurring during HCV and also HBV liver diseases [17].
In this setting, we have explored the lipid profile of SC and CHC patients, but similar to miRNA
results, both profiles were similar with no statistically significant differences among them. Similar
results were found in a small study on CHC and SC Mexican patients [40], where both groups showed
similarities in lipid profile but differences in liver enzymes and cytokines. However, a lipidomic
analysis on the serum of HCV-resistant cases showed clear differences from HCV antibody-positive
individuals, even those who clear viremia either spontaneously or after antiviral therapy [41].
MiR-21-3p was upregulated in HCV-exposed subjects (CHC and SC groups). This miRNA is also
upregulated (up to 21-fold) in HCV in vitro infection [28], where its increase allows HCV to evade the
immune surveillance system. This miRNA targets two crucial factors in the TLR signaling pathway,
myeloid differentiation factor 8 (MyD88) and interleukin-1 receptor-associated kinase 1 (IRAK1), which are both
involved in HCV-induced type I interferon production. Therefore, miR-21 is considered as a potential
therapeutic target for HCV antiviral therapy as it negatively regulates interferon-alpha signaling.
The miR-21 expression has also been positively correlated with the fibrotic stage and could lead to
increased fibrogenesis by targeting genes belonging to the transforming growth factor (TGF)-β signaling
pathway [42]. Regarding miR-21 effects on fatty acid metabolism pathway, this molecule targets some
essential genes such as insulin-like growth factor binding protein 3 (IGFBP3), fatty acid-binding protein 7
(FABP7), and peroxisome proliferator-activated receptor alpha (PPARα) [39], which regulate cell growth,
intracellular trafficking of fatty acids, and and gene transcription of fatty acid metabolism, respectively.
MiR-124-3p, a key regulator of fatty acid oxidation and triglyceride (TG) metabolism [43],
is also involved in Treg cell development during an HCV infection [44]. Through the targeting of
multiple genes, miR-124-3p produces a cooperative inhibitory effect on lipid catabolism, leading to
TG accumulation in human hepatoma Huh7.5 cells. Our data show an upregulation of miR-124-3p in
PBMCs during and after an HCV infection, which may be related to a lipid accumulation to facilitate
HCV replication. This miRNA was one of the most important in HCV-exposed vs. non-exposed
individuals in the PLS-DA.
hsa-miR-125a-5p and 125b-5p were both detected as downregulated in PBMCs in the CHC and
SC groups. These miRNAs are encoded by genes located at different chromosomes but share closely
related mature sequences and seed family. Thus, both miRNAs target similar genes and regulate
related pathways, such as the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20), a negative
regulator of the NF-κB pathway [45] that has been previously associated with liver fibrosis and
inflammation in an HCV infection [46]. Bala et al. also found that miR-125b-5p was downregulated in
monocytes of HCV chronic patients compared to healthy controls [47]. Regarding lipid metabolism,
miR-125a-5p negatively regulates the scavenger receptor class B type I (SR-BI), which encodes for
the receptor that captures the cholesterol esters from HDL particles for steroidogenesis, mainly in
hepatocytes [48]. Therefore, the downregulation of miR-125a-5p will produce a higher expression of
SR-BI and, consequently, a higher uptake of cholesterol in PBMCs, which could facilitate HCV infection.
On the other hand, miR-125b-5p seems to play a vital role in lipogenesis by targeting the stearoyl-CoA
desaturase-1 (SCD-1) gene, which encodes for a key enzyme in lipogenesis in which inhibition impairs
lipid synthesis [49]. Thus, the downregulation of this miRNA in the context of an HCV infection could
be related to an increase of fatty acid deposits within infected cells, which would again benefit the
HCV viral cycle.
4.2. Additional Disrupted Pathways in PBMCs After HCV Infection
Further signaling pathways were significantly identified in a functional enrichment analysis of
the 21 SDE miRNAs. The Hippo signaling pathway is an evolutionarily conserved pathway that
controls organ size by regulating cell growth and proliferation. Previous studies have identified
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the inactivation of this pathway in the development of hepatocellular carcinoma (HCC) [50–52],
and it is interconnected with other crucial signaling cascades such as TGF-beta and Wnt growth
factors. Interestingly, this pathway has a key role in pathogen-infected cells by regulating innate
antiviral immunity [53]. Also, some virus and bacteria can exploit hippo signaling to enhance
pathogenicity by evading host innate immunity. Our data indicate that this pathway is disrupted in
PBMCs of HCV-exposed individuals (CHC and SC groups) by the upregulation of hsa-miR-125a-5p,
hsa-miR-125b-5p, and hsa-miR-3960 and by the downregulation of hsa-miR-582-3p.
On the other hand, the extracellular matrix (ECM) interaction pathway (hsa04512) seems to be
dysregulated in PBMCs in active and previous HCV exposure. This pathway is involved in liver
fibrosis development, which is triggered by an HCV infection through the activation of hepatic stellate
cells (HSCs) [54]. The ECM is involved in the regulation of the interferon signaling pathway and
HCV-RNA replication [55]. PBMCs contribute to systemic and regional inflammation and matrix
remodeling in some model diseases, such as cardiac disease [56] and obesity [57]. Therefore, it is
reasonable that PBMCs from patients exposed to HCV show a disruption of the ECM pathway as a
consequence of HCV presence within these cells [58].
Proteoglycans-related pathways (hsa05205 and hsa00514) are also disrupted. These pathways
have been described as responsible for the tissue-specific tropism of an HCV infection [58], and some
studies have identified the involvement of proteoglycans, such as heparan sulfate, in HCV attachment
and postattachment steps [59]. Three SDE miRNAs were upregulated in HCV-exposed patients
(miR-21-3p, miR-124-3p, and miR-582-3p) and three were downregulated (miR-125a-5p, miR-125b-5p,
and miR-122-5p). Therefore, HCV infections could be modifying specific cell-surface proteoglycans of
infected cells through miRNA disruption to facilitate HCV attachment.
Also, we identified the steroid biosynthesis pathway (hsa00100) as dysregulated in HCV-exposed
individuals. A previous expression analysis of in vitro experiment in naïve, HCV-infected, and cured
cells showed that the steroid biosynthesis is one of the significantly altered pathways, suggesting
that, among others, it is required for an efficient HCV replication [60]. Steroid enzymes are
responsible for the biosynthesis of various steroid hormones such as glucocorticoids, mineralocorticoids,
progestins, androgens, and estrogens from cholesterol. This closely related pathway to lipid and
cholesterol metabolism has also an essential role in immune cell-mediated metabolic regulation and
immunomodulation [61]. Thus, our data indicate that, during chronic and after a spontaneously
resolved HCV infection, PBMCs show an upregulation of miR-21-3p (which target DHCR4 and
NSDHL) and miR-124-3p (which targets SC5D, DHCR24, LIPA, and FAXDC2) and the downregulation
of miR-23a-5p (which also targets DHCR24). This complex deregulation of cholesterol and steroid
biosynthesis enzymes seems to be modified by HCV infections to promote a permissive HCV
infective environment.
4.3. HCV-Related Genes
We have analyzed the implication of the 21 SDE miRNAs in targeting host genes related to HCV
infection, and nine out of 21 SDE miRNAs were identified. The most relevant miRNA in this analysis
was the has-miR-124-3p, which was upregulated in HCV-exposed individuals, and it targets 18 HCV
infection-related genes. HCV infection requires multiple host signaling pathways to successfully infect
the host cell, and it has developed strategies to disrupt the induction of IFN and cytokine pathways,
favoring viral propagation and presumably HCV chronic infections [62]. Our results suggest that
the subverts of miRNAs is an additional strategy of HCV to maintain infection [8] and to establish
an antiviral stage. Thus, the upregulation of hsa-miR-124 in PBMCs by HCV will downregulate
IFN production at different pathway levels, such as the IFN alpha/beta pathway [63], the PI3K/AKT
signaling pathway [64], and the MAPK/ERK cascade which is used by HCV for viral propagation [65].
Here, we review the most relevant targets of this miRNA and their biological functions.
HCV interacts with components of the IFN alpha/beta pathway to inhibit IFN production,
and the hsa-miR-124-3p can target seven members of this signalling pathway: the toll-like receptor 3
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(TLR3), the inhibitor of nuclear factor kappa B kinase subunit epsilon (IKBKE), the eukaryotic translation
initiation factor 2 alpha kinase 2 (EIF2AK2), the interferon-alpha/beta receptor 2 (IFNAR2), the tyrosine
kinase 2 (TYK2), the protein inhibitor of activated STAT 1 (PIAS1), and RELA proto-oncogene (RELA).
Thus, the overexpression of has-miR-124-3p may act as an additional strategy to disrupt the host
antiviral state.
HCV also activates PI3K-Akt signaling to enhance entry, replication, and translation [66,67].
Three main factors of this pathway targeted by has-miR-124 are the phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit alpha (PIK3CA) and the AKT serine/threonine kinase 2 (AKT2) and 3 (AKT3).
The assault by HCV on this pathway that regulates cell growth and metabolism probably plays an
important role in HCV pathogenesis.
HCV also modulates the MAPK/ERK cascade for its own propagation [65]. Eight genes within
this pathway can be targeted by the hsa-miR-124-3p: the growth factor receptor-bound protein 2
(GRB2), SOS Ras/Rho guanine nucleotide exchange factor 1 (SOS1) and 2 (SOS2), A-Raf proto-oncogene,
cytosolic serine/threonine kinase (ARAF), the GTPase neuroblastoma RAS proto-oncogene (NRAS) [68],
the mitogen-activated protein kinase 11 (MAPK11), the protein phosphatase 2 scaffold subunit Abeta (PPP2R1B),
and the cyclin-dependent kinase inhibitor 1A (CDKN1A) also known as p21. Different viruses such as HCV
interact with this pathway to specifically subvert key survival pathways for the host [69]. Therefore,
the upregulation of hsa-miR-124 by an HCV infection will repress the RAS-MAPK signaling pathway
at different levels to ultimately regulate HCV RNA replication.
4.4. HCV Spontaneous Clarification
The common miRNA profile between SC and CHC suggests that an HCV infection promotes
molecular alterations that will last long after an HCV spontaneous eradication. Our cohort with
36 spontaneous clarifiers was recruited from routine controls, where anti-HCV antibodies were detected
a long time after infection (up to 47 years). There is not much information on the dynamics of antibodies
against HCV in patients who eliminated an HCV infection [70,71]. Most of the studies have been
focused on the anti-HCV antibody levels of CHC patients after IFN therapy, but scarce studies have
analyzed the anti-HCV dynamics after a spontaneous clarification [4,72]. Takaki et al. reported that
HCV-specific antibodies were lost in some patients 18–20 years after recovery from an acute-phase
of HCV infection [4], while positive HCV antibodies can be detected even 18 years after inoculation,
as it has been previously identified in a cohort of HCV spontaneously resolved Irish women [73].
These findings suggest that SC may be underestimated in the general population, as antibodies
anti-HCV can be lost over time in some individuals.
Several comorbidities such as steatosis and nonalcoholic steatohepatitis had been previously
observed at a higher frequency in these Irish patients [74]. They analyzed biopsies from HCV
PCR-negative individuals with the modified histological activity index (HAI), and a high proportion of
steatosis was reported, as well as mild inflammation and steatohepatitis. Then, the authors suggested
a “cleared past exposure” in the liver of spontaneously resolved patients.
Our results indicate that the SC group suffer from PBMCs-fatty acid metabolism disruption,
which could reflect liver status. Previous evidence supports this idea as the fatty liver is predominant
in HCV patients after the achievement of sustained virological response [75] and the HCV cure does
not lead to complete immunological restitution [76]. A prior history of spontaneously resolved HCV
infections may promote hepatic injury in those patients with non-alcoholic fatty liver disease (NAFLD)
or alcohol-related liver disease, but this field remains unexplored. Therefore, an additional follow-up
of previously HCV-exposed patients should be carried out to explore putative future complications
such as liver diseases, among others.
Therefore, the availability of biomarkers to identify HCV-exposed individuals is essential. Hence,
our 21 miRNA signature could be used to identify SC patients with undetectable antibodies against HCV.
Future studies will be required to delve into the role of these 21 SDE miRNA identified during
and after an HCV infection and their implication in the immune restoration of PBMCs.
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Finally, some additional considerations should be taken into account to interpret our results
properly. The lipid profile of HC could not be recorded, so we could not analyze the differences
compared to the HC and CHC groups. The immune host-related background has a strong influence on
the spontaneous clearance of an HCV infection, which variates with ethnicity and gender. Our study has
been carried out entirely in Caucasian patients, and it would be necessary to perform an independent
replication of this study for different ethnic groups. Also, our cohort of patients was sex balanced,
with the same proportion of males and females. This design allows us to remove gender bias, as it
has been widely described that females clarify HCV in a higher proportion than men. The protective
allele of IFNL4 (rs12979860) showed a higher frequency in SC patients, which has been strongly
associated with a spontaneous HCV clearance irrespective of the HCV-infected genotype, and reflects
the spontaneous resolution genetic background of these patients.
5. Conclusions
Our data indicate that HCV spontaneous resolved individuals and HCV chronic patients showed
a similar disruption of miRNA profile at PBMCs with respect to healthy controls. This disruption is
reflected in a fingerprint of 21 miRNAs that correctly differentiates HCV-exposed individuals from
non-exposed. These miRNAs mainly regulates fatty acid metabolism. Therefore, a spontaneous
clarification of HCV during an acute infection leads to molecular changes that can be subsequently
observed on the miRNA profile of PBMCs.
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